EP1062319A4 - Vascular endothelial growth factor 2 - Google Patents

Vascular endothelial growth factor 2

Info

Publication number
EP1062319A4
EP1062319A4 EP99912320A EP99912320A EP1062319A4 EP 1062319 A4 EP1062319 A4 EP 1062319A4 EP 99912320 A EP99912320 A EP 99912320A EP 99912320 A EP99912320 A EP 99912320A EP 1062319 A4 EP1062319 A4 EP 1062319A4
Authority
EP
European Patent Office
Prior art keywords
growth factor
vascular endothelial
endothelial growth
vascular
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912320A
Other languages
German (de)
French (fr)
Other versions
EP1062319A1 (en
Inventor
Craig A Rosen
Liang Cao
Jing-Shan Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/042,105 external-priority patent/US6040157A/en
Priority claimed from US09/107,997 external-priority patent/US7186688B1/en
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1062319A1 publication Critical patent/EP1062319A1/en
Publication of EP1062319A4 publication Critical patent/EP1062319A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
EP99912320A 1998-03-13 1999-03-10 Vascular endothelial growth factor 2 Withdrawn EP1062319A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/042,105 US6040157A (en) 1994-03-08 1998-03-13 Vascular endothelial growth factor 2
US42105 1998-03-13
US09/107,997 US7186688B1 (en) 1994-03-08 1998-06-30 Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US107997 1998-06-30
PCT/US1999/005021 WO1999046364A1 (en) 1998-03-13 1999-03-10 Vascular endothelial growth factor 2

Publications (2)

Publication Number Publication Date
EP1062319A1 EP1062319A1 (en) 2000-12-27
EP1062319A4 true EP1062319A4 (en) 2003-04-23

Family

ID=26718873

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912320A Withdrawn EP1062319A4 (en) 1998-03-13 1999-03-10 Vascular endothelial growth factor 2

Country Status (7)

Country Link
EP (1) EP1062319A4 (en)
JP (1) JP2002505873A (en)
KR (1) KR20010034576A (en)
CN (1) CN1299407A (en)
AU (1) AU3072099A (en)
CA (1) CA2322748A1 (en)
WO (1) WO1999046364A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414016A1 (en) 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ATE242809T1 (en) 1995-09-08 2003-06-15 Genentech Inc VEGF-RELATED PROTEIN
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
EP1017421B1 (en) * 1997-03-07 2005-05-25 The Wistar Institute Of Anatomy And Biology Use of adenoviral vectors expressing VEGF or PDGF FOR HEALING TISSUE DEFECTS AND INDUCING HYPERVASCULARITY IN MAMMALIAN TISSUE
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
ES2551160T3 (en) 2000-04-12 2015-11-16 Vib Vzw Use of VEGF and homologs to treat neurological disorders
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2004536579A (en) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Vascular endothelial growth factor 2
WO2003018752A2 (en) 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
WO2003081201A2 (en) * 2002-03-21 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004247026B2 (en) * 2003-05-16 2009-09-24 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of CNS
US8226941B2 (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
SI1755647T1 (en) 2004-05-27 2011-01-31 Vib Vzw Treatment of amyotrophic lateral sclerosis
EP1869075B1 (en) 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Anti-angiogenic methods and compositions
WO2007038548A2 (en) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
CN100448892C (en) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 Antitumour vascular endothelial growth factor receptor VEGF-R antigen and its coding gene and application
EP2450442B1 (en) 2006-10-10 2017-07-19 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024473A1 (en) * 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
WO1996039515A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
WO1997005250A2 (en) * 1995-08-01 1997-02-13 Helsinki University Licensing Ltd. Oy Receptor ligand vegf-c
WO1997009427A1 (en) * 1995-09-08 1997-03-13 Genentech, Inc. Vegf-related protein
WO1997017442A1 (en) * 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2212121T3 (en) * 1996-08-13 2004-07-16 Human Genome Sciences, Inc. MUTANTS OF QUERANOCITIC GROWTH FACTOR-2 (KGF-2 OR FIBROBLASTIC GROWTH FACTOR -12, FGF-12).

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024473A1 (en) * 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
WO1996039515A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
WO1997005250A2 (en) * 1995-08-01 1997-02-13 Helsinki University Licensing Ltd. Oy Receptor ligand vegf-c
WO1997009427A1 (en) * 1995-09-08 1997-03-13 Genentech, Inc. Vegf-related protein
WO1997017442A1 (en) * 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9946364A1 *

Also Published As

Publication number Publication date
KR20010034576A (en) 2001-04-25
AU3072099A (en) 1999-09-27
WO1999046364A9 (en) 1999-11-18
EP1062319A1 (en) 2000-12-27
CA2322748A1 (en) 1999-09-16
CN1299407A (en) 2001-06-13
WO1999046364A1 (en) 1999-09-16
JP2002505873A (en) 2002-02-26

Similar Documents

Publication Publication Date Title
EP1062319A4 (en) Vascular endothelial growth factor 2
EP1313512A4 (en) Vascular endothelial growth factor 2
EP1385862A4 (en) Vascular endothelial growth factor 2
AU5439998A (en) Vascular endothelial growth factor
SG117417A1 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
AU2002256172A1 (en) Vascular endothelial growth factor 2
AU5023300A (en) Vascular endothelial growth factor variants
EP1137805A4 (en) Methods of facilitating vascular growth
EP0873348A4 (en) Human vascular endothelial growth factor 3
EP0904292A4 (en) Growth differentiation factor-14
GB9722604D0 (en) Heparin-binding growth factor derivatives
EP0550296A3 (en) Vascular endothelial cells growth factor
AU5026100A (en) Vascular endothelial growth factor dimers
EP0832215A4 (en) Fibroblast growth factor 11
EP0796325A4 (en) Human vascular ibp-like growth factor
EP0832216A4 (en) Fibroblast growth factor 15
AU5440800A (en) Fibroblast growth factor 10
GB9828377D0 (en) Vascular endothelial growth factor-e
AU4851200A (en) Fibroblast growth factor 11
AU5268000A (en) Fibroblast growth factor 15
AU3147799A (en) Para-poxvirus-coded vascular endothelial cell growth factor (ppv-vegf)
GB9901323D0 (en) Freeface 1
EP0891372A4 (en) Growth factor htter36
AU6951400A (en) Fibroblast growth factor 13
AU5019700A (en) Fibroblast growth factor 14

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030306

17Q First examination report despatched

Effective date: 20050608

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051011